|
Enaleni - Results Of General Meeting Of Enaleni Ordinary Shareholders
Warning: The listing of ordinary shares in the company is on ALTx. Investors
are advised of the risks of investing in a company listed on ALTx. Investors are
advised that the JSE does not guarantee the viability or the success of a
company listed on ALTx. In terms of the Listings Requirements, the company is
obliged to appoint and retain a Designated Adviser, which is required to, inter
alia, attend all board meetings held by the company to ensure that all the
Listings Requirements and applicable regulations are complied with, approve the
Financial Director of the company and guide the company in a competent,
professional and impartial manner. If the company fails to retain a Designated
Adviser, it must make arrangements to appoint a new Designated Adviser within 10
business days, failing which the company faces suspension of trading of its
securities. If a Designated Adviser is not appointed within 30 days of its
suspension, the company faces the termination of its listing without the
prospect of an appropriate offer to minority shareholders.
Enaleni Pharmaceuticals Limited
(Incorporated in the Republic of South Africa)
(Registration number 2002/018027/06)
(JSE code: ENL ISIN: ZAE000067740)
("Enaleni" or "the company")
RESULTS OF GENERAL MEETING OF ENALENI ORDINARY SHAREHOLDERS ("SHAREHOLDERS")
Further to the circular issued to Shareholders dated 28 November 2005 ("the
circular"), Shareholders are advised that at the general meeting of Shareholders
held on Tuesday, 13 December 2005, the requisite number of Shareholders voted in
favour of the ordinary resolutions necessary to implement the acquisition of all
the issued share capital of Cipla Medpro Holdings (Pty) Limited ("the
transaction"), to effect amendments to the Enaleni share incentive scheme trust,
the authorisation to offer Enaleni ordinary share options to certain employees
at 300 cents per ordinary share as contained in the circular and the
authorisation for the directors to sign all the documentation necessary to
implement the transaction.
Accordingly the board of Enaleni announces that the transaction is now
unconditional in all respects.
The JSE Limited has approved the listing of an additional 284 465 768 ordinary
shares in Enaleni with effect from Wednesday, 14 December 2005 and the transfer
of Enaleni"s listing from ALTx to the JSE main board on Thursday, 15 December
2005.
Transactional Designated Adviser, Investment Bank and Joint Corporate Adviser
and Arranger
Nedbank Capital
Designated Adviser and Joint Corporate Adviser and Arranger
Exchange Sponsors
Transactional Independent Sponsor
KPMG Services (Pty) Limited
Independent Auditors and Reporting Accountants
KPMG Inc.
Independent Auditors and Reporting Accountants to Cipla Medpro
Moores Rowland
Attorneys
Deneys Reitz Inc.
Transfer Secretaries
Computershare Investor Services 2004 (Pty) Limited
Johannesburg
13 December 2005
Date: 13/12/2005 05:20:54 PM Produced by the JSE SENS Department
| Profile Group (Pty) Ltd. has taken care in preparing all information on this website, but does not accept any liability for errors or out-of-date information. | |||||||||||||
| Other Profile Group sites: FundsData Online (unit trust data) | Profile Group corporate site | |||||||||||||
| [ Terms of Use | Privacy Policy | PAIA manual | FAQs/Help | Site Map | © Copyright Reserved 2026 ] | |||||||||||||
|
|||||||||||||
